FOURTH AMENDMENT TO DEVELOPMENT AND LICENSE AGREEMENTDevelopment and License Agreement • August 15th, 2011 • NPS Pharmaceuticals Inc • Biological products, (no disgnostic substances)
THIS FOURTH AMENDMENT (the “Fourth Amendment”) to the DEVELOPMENT AND LICENSE AGREEMENT by and between NPS Pharmaceuticals, Inc. (“NPS”) and Amgen Inc. (“Amgen”) is dated as of August 10, 2011. NPS and Amgen are referred to in this Fourth Amendment individually as a “Party” and collectively as the “Parties”. Additionally, Royalty Sub (as defined below) hereby acknowledges and agrees to the provisions contained in this Fourth Amendment. Certain terms used herein but not otherwise defined herein shall have the respective meanings set forth in the Agreement (as defined below).
